Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
clinical oncology department at Al Demerdash hospital
Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC).
Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2.
Age >18 years.
Adequate bone marrow reserve
Presence of Central nervous system(CNS) metastases.
Inadequate liver function
Inadequate renal function
Serious comorbid systemic disorder incompatible with the study.